Clinico-Pathologic and Biologic Predictors of EGFR Inhibitors Activity and Efficacy in Lung and in Colorectal Cancer

Publisher： Bentham Science Publishers

E-ISSN： 2212-389x|3|3|234-243

ISSN： 1574-3624

Source： Current Signal Transduction Therapy, Vol.3, Iss.3, 2008-09, pp. : 234-243

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Clinical Predictors of Response to EGFR Tyrosine Kinase Inhibitors in Patients with EGFR-Mutant Non-Small Cell Lung Cancer

By  

Oncology, Vol. 86, Iss. 2, 2014-01 ,pp. : 86-93

Karger

Access to resources Recommend Favorite

EGFR Inhibitors in the Treatment of Lung Cancer

By  

Oncology Research and Treatment, Vol. 30, Iss. 10, 2007-09 ,pp. : 476-476

Karger

Access to resources Recommend Favorite

A clinico‐pathologic study of placenta percreta

By  

International Federation of Gynecology and Obstetrics, Vol. 140, Iss. 3, 2018-03 ,pp. : 365-369

John Wiley & Sons Inc

Access to resources Recommend Favorite

HGF-MET in Resistance to EGFR Tyrosine Kinase Inhibitors in Lung Cancer

By  

Current Signal Transduction Therapy, Vol. 6, Iss. 2, 2011-05 ,pp. : 228-233

Bentham Science Publishers

Access to resources Recommend Favorite

The Clinico-Pathologic Role of MicroRNAs miR-9 and miR-151-5p in Breast Cancer Metastasis

By Krell Jonathan  

Molecular Diagnosis & Therapy, Vol. 16, Iss. 3, 2012-06 ,pp. : 167-172

Adis International

Access to resources Recommend Favorite